Paloma Partners’s BioMarin Pharmaceuticals BMRN Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2024
Q4 | – | Sell |
-3,402
| Closed | -$239K | – | 374 |
|
|
2024
Q3 | $239K | Buy |
+3,402
| New | +$284K | 0.01% | 908 |
|
|
2024
Q2 | – | Sell |
-421
| Closed | -$36.8K | – | 1258 |
|
|
2024
Q1 | $36.8K | Buy |
421
+157
| +59% | +$14.1K | ﹤0.01% | 699 |
|
|
2023
Q4 | $25.5K | Sell |
264
-1,570
| -86% | -$139K | ﹤0.01% | 682 |
|
|
2023
Q3 | $162K | Buy |
+1,834
| New | +$163K | 0.01% | 600 |
|
|
2023
Q1 | – | Sell |
-2,550
| Closed | -$264K | – | 765 |
|
|
2022
Q4 | $264K | Hold |
2,550
| – | – | 0.01% | 659 |
|
|
2022
Q3 | $216K | Sell |
2,550
-8,075
| -76% | -$719K | 0.01% | 691 |
|
|
2022
Q2 | $881K | Buy |
10,625
+6,655
| +168% | +$530K | 0.03% | 461 |
|
|
2022
Q1 | $306K | Buy |
+3,970
| New | +$332K | 0.01% | 1124 |
|
|
2021
Q3 | – | Sell |
-11,727
| Closed | -$979K | – | 1129 |
|
|
2021
Q2 | $979K | Sell |
11,727
-3,258
| -22% | -$258K | 0.02% | 650 |
|
|
2021
Q1 | $1.13M | Buy |
14,985
+7,707
| +106% | +$630K | 0.02% | 636 |
|
|
2020
Q4 | $639K | Sell |
7,278
-27,179
| -79% | -$2.15M | 0.02% | 774 |
|
|
2020
Q3 | $2.62M | Buy |
34,457
+32,157
| +1,398% | +$3.25M | 0.07% | 305 |
|
|
2020
Q2 | $284K | Sell |
2,300
-3,100
| -57% | -$308K | ﹤0.01% | 1501 |
|
|
2020
Q1 | $456K | Buy |
5,400
+1,817
| +51% | +$157K | 0.03% | 535 |
|
|
2019
Q4 | $303K | Sell |
3,583
-21,716
| -86% | -$1.64M | ﹤0.01% | 1745 |
|
|
2019
Q3 | $1.71M | Buy |
25,299
+21,555
| +576% | +$1.66M | 0.04% | 501 |
|
|
2019
Q2 | $320K | Sell |
3,744
-17,485
| -82% | -$1.5M | 0.01% | 1262 |
|
|
2019
Q1 | $1.89M | Buy |
21,229
+18,270
| +617% | +$1.69M | 0.05% | 474 |
|
|
2018
Q4 | $253K | Sell |
2,959
-4,397
| -60% | -$418K | 0.01% | 940 |
|
|
2018
Q3 | $713K | Buy |
7,356
+2,431
| +49% | +$243K | 0.01% | 883 |
|
|
2018
Q2 | $464K | Sell |
4,925
-5,513
| -53% | -$483K | 0.01% | 1068 |
|
|
2018
Q1 | $847K | Buy |
10,438
+2,636
| +34% | +$226K | 0.01% | 1075 |
|
|
2017
Q4 | $696K | Sell |
7,802
-301
| -4% | -$26.2K | 0.01% | 1214 |
|
|
2017
Q3 | $754K | Sell |
8,103
-14,315
| -64% | -$1.26M | 0.01% | 1309 |
|
|
2017
Q2 | $2.04M | Buy |
22,418
+6,302
| +39% | +$573K | 0.02% | 743 |
|
|
2017
Q1 | $1.42M | Sell |
16,116
-12,730
| -44% | -$1.13M | 0.02% | 1020 |
|
|
2016
Q4 | $2.39M | Buy |
28,846
+6,251
| +28% | +$538K | 0.02% | 571 |
|
|
2016
Q3 | $2.09M | Buy |
22,595
+1,771
| +9% | +$167K | 0.03% | 525 |
|
|
2016
Q2 | $1.62M | Buy |
20,824
+17,290
| +489% | +$1.47M | 0.02% | 852 |
|
|
2016
Q1 | $292K | Buy |
+3,534
| New | +$288K | ﹤0.01% | 1532 |
|
|
2015
Q4 | – | Sell |
-10,009
| Closed | -$1.05M | – | 1711 |
|
|
2015
Q3 | $1.05M | Sell |
10,009
-92,591
| -90% | -$12.4M | 0.02% | 625 |
|
|
2015
Q2 | $14M | Buy |
102,600
+94,904
| +1,233% | +$11.8M | 0.27% | 76 |
|
|
2015
Q1 | $959K | Sell |
7,696
-3,691
| -32% | -$391K | 0.03% | 506 |
|
|
2014
Q4 | $1.03M | Sell |
11,387
-12,039
| -51% | -$1M | 0.04% | 424 |
|
|
2014
Q3 | $1.69M | Sell |
23,426
-11,677
| -33% | -$767K | 0.08% | 255 |
|
|
2014
Q2 | $2.18M | Buy |
+35,103
| New | +$2.12M | 0.09% | 212 |
|
Other funds holding BMRN
EIM
Paloma Partners's BMRN Position: Q4 2024 in Review
Paloma Partners sold out of BioMarin Pharmaceuticals (BMRN) in Q4 2024, closing a stake of 3,402 shares — an estimated $239K sold.
Paloma Partners first reported a position in BMRN in Q2 2014 and held it in 36 quarters. The position peaked at $14M in Q2 2015. 545 funds tracked by Wall St. Rank hold BMRN as of Q4 2024.
- Paloma Partners reported no remaining BioMarin Pharmaceuticals position as of Q4 2024 after selling out during the quarter.
- Paloma Partners sold 3,402 BioMarin Pharmaceuticals shares in Q4 2024, an estimated $239K.
- Paloma Partners first reported a position in BioMarin Pharmaceuticals in Q2 2014 and held it in 36 quarters.
- Paloma Partners's BioMarin Pharmaceuticals position peaked at $14M in Q2 2015.
- 545 funds tracked by Wall St. Rank held BioMarin Pharmaceuticals as of Q4 2024.
Based on Paloma Partners's 13F filing for Q4 2024, filed 14 Feb 2025.